Propel Bio Management, LLC Q4 2024 Filing

Filed February 14, 2025

Portfolio Value

$100.7B

Holdings

21

Report Date

Q4 2024

Filing Type

13F-HR

All Holdings (21 positions)

#StockSharesValue% PortfolioType
1
PAGPPLAINS GP HOLDINGS LP-CL
1,272,360$23.4B23.23%
2
MDGLMADRIGAL PHARMACEUTICALS
43,032$13.3B13.19%
3
AKROAKERO THERAPEUTICS INC
343,729$9.6B9.50%
4
SP4PACHIEVE LIFE SCIENCES INC
2,453,092$8.6B8.58%
5
APLTAPPLIED THERAPEUTICS INC
9,615,420$8.2B8.18%
6
PHATPHATHOM PHARMACEUTICALS I
989,927$8.0B7.98%
7
TCRXTSCAN THERAPEUTICS INC
2,087,139$6.3B6.30%
8
RNAAVIDITY BIOSCIENCES INC
178,500$5.2B5.16%
9
ARDXARDELYX INC
950,947$4.8B4.79%
10
ABEOABEONA THERAPEUTICS INC
624,022$3.5B3.45%
11
SNDXSYNDAX PHARMACEUTICALS IN
183,259$2.4B2.41%
12
KYMRKYMERA THERAPEUTICS INC
56,359$2.3B2.25%
13
ZVRAZEVRA THERAPEUTICS INC
179,874$1.5B1.49%
14
KURAKURA ONCOLOGY INC
130,000$1.1B1.12%
15
ATHIRA PHARMA INC
1,492,792$875.8M0.87%
16
72CEIGER BIOPHARMACEUTICALS
146,381$765.0M0.76%
17
JSPRJASPER THERAPEUTICS INC
20,000$427.6M0.42%
18
DCTHDELCATH SYSTEMS INC
17,000$204.7M0.20%
19
CMPSCOMPASS PATHWAYS PLC
25,209$95.3M0.09%
20
MAAT PHARMA SACA
3,151$25.1M0.02%
21
CHINOOK THERAPEUTICS
79,357$9.8M0.01%